Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 2/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4282197 | 0.82 | RET (0.36) | KDR | |
| SCHEMBL4285394 | 0.75 | KDR (0.33) | KDR | |
| SCHEMBL4280047 | 0.72 | KDR (0.42) | NPC1RAB9AKDRKDM4C | |
| SCHEMBL4279705 | 0.68 | KDR (0.37) | KDR | |
| SCHEMBL30896131 | 0.68 | RORC (0.37) | GCKNPC1RAB9AKDM4CRORC | |
| SCHEMBL21170736 | 0.65 | CSF1R (0.45) | GCKNPC1RAB9AKDM4CRORC | |
| SCHEMBL30896098 | 0.64 | KDM4C (0.38) | GCKNPC1RAB9AKDM4CRORC | |
| SCHEMBL4284118 | 0.64 | RET (0.38) | RAB9AKDR | |
| SCHEMBL6288510 | 0.64 | GRM5 (0.43) | GCKNPC1RAB9AKDM4CRORC | |
| SCHEMBL4292419 | 0.64 | EGFR (0.36) | KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137580-A1 | Fused Heterocyclic Derivatives and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1904498-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007004749-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137580-A1 | Fused Heterocyclic Derivatives and Use Thereof | TIE1, KDR, FLT1 | GCK 2751/4885NPC1 4628/4885RAB9A 3416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.